ClinicalTrials.gg
CompletedNCT02283177Updated Feb 2, 2024Results posted

A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations

A Phase 2 interventional study of crenolanib and cytarabine in Newly Diagnosed AML With FLT3 Activating Mutations, sponsored by Arog Pharmaceuticals, Inc.. Completed at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-02.

Sponsored by Arog Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
44
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This pilot study is designed to evaluate the safety and tolerability of oral crenolanib besylate given sequentially during standard induction and consolidation chemotherapy in patients with newly diagnosed AML with FLT3 activating mutations.

02

Conditions studied

  • Newly Diagnosed AML With FLT3 Activating Mutations
03

In context

Lead sponsor

Arog Pharmaceuticals, Inc. is the lead sponsor of 17 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Unequivocal diagnosis of AML based on the WHO classification, excluding acute promyelocytic leukemia
  2. No prior therapy for AML, except for hydroxyurea, in this setting is allowed.
  3. Subjects with AML evolving from MDS may have received prior MDS therapy with demethylating agents
  4. Subjects must have tested positive for FLT3-ITD and/or other FLT3 activating mutations
  5. Age ≥18 years
  6. PS 0 - 2
  7. Adequate liver function, defined as normal total , ≤2.0x , and AST ≤2.0x ULN measured within 24 hours prior to crenolanib commencement
  8. Adequate renal function, defined as serum creatinine ≤1.5x ULN or >50 mL/min
  9. Negative pregnancy test (serum or urine) for women of (WOCBP)

    • Women considered not of childbearing potential include any of the following: no menses for at least 2 years or menses within 2 years but amenorrheic for at least 2 months and luteinizing hormone (LH) and follicular stimulating hormone (FSH) values within normal range (according to definition of for laboratory used) or bilateral oophorectomy or radiation castration and amenorrheic for at least 3 months or with bilateral tubal ligation
  10. WOCBP must practice . Acceptable methods of contraception are double barrier methods (condoms with spermicidal jelly or foam and diaphragm with spermicidal jelly or foam), oral, depo provera, or injectable contraceptives, intrauterine devices, tubal ligations, and abstention
  11. Male patients (except those with prior surgical contraceptive procedures) with female partners who are of childbearing potential: Recommendation is for male and partner to use effective contraceptive methods, such as latex condoms, during the study
  12. Able and willing to provide written

Exclusion criteria

Exclusion Criteria:

  1. Pre-existing liver diseases (i.e., cirrhosis, chronic or C, nonalcoholic steatohepatitis, and sclerosing cholangitis, etc.)
  2. Active CNS leukemia
  3. Subject with concurrent severe and/or uncontrolled medical conditions that in the opinion of the investigator may impair the participation in the study or the evaluation of safety and/or efficacy
  4. Class III-IV heart failure, myocardial infarction \<6 months prior to study entry, and/or serious arrhythmia requiring anti-arrhythmic therapy
  5. Unable to swallow pills
  6. Major surgical procedures within 14 days of administration of crenolanib (does not include line placement as needed for chemotherapy administration).
  7. Unwillingness or inability to comply with protocol.
  8. Concurrent use of other agents.
  9. Subjects who are not eligible for standard chemotherapy
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    Cohort A

    Patients will be given cytarabine and daunorubicin during induction therapy plus crenolanib at 100 mg TID.

    Drug: crenolanib · Drug: cytarabine · Drug: daunorubicin

  • Experimental
    Cohort B

    Patients will be given cytarabine and idarubicin during induction therapy plus crenolanib at 100 mg TID.

    Drug: crenolanib · Drug: cytarabine · Drug: idarubicin

Interventions

06

What researchers measure

Primary outcomes

  1. Clinical Response to Crenolanib With Standard Induction Chemotherapy

    To determine the response rate to crenolanib. Complete remission (CR) response criteria includes a post-baseline bone marrow (BM) biopsy or aspiration % blasts \<5%, the absence of Auer rods and extramedullary leukemia, absolute neutrophil count (ANC) \>1×10\^9/L and platelet count \>100×10\^9/L. Complete remission with incomplete blood count recovery (CRi) response includes all CR criteria met, except participant do not achieve either platelet or ANC recovery. Composite Complete CR response includes all subjects who achieve a CR and CRi. Partial Response (PR) response includes all CR criteria met except a decrease of ≥50% in % blasts in the BM aspirate or biopsy from baseline but within 5-25% or bone marrow blasts \<5% with persistent Auer rods. Refractory Disease response includes subjects who do not satisfy the criteria for CR, CRi or PR.

    Time frame: 2 years

Secondary outcomes

  1. 3-Year Overall Survival

    Overall survival (OS) was measured from the date of the first dose of treatment to the date of death from any cause or to the last date that the patient was known to be alive. OS at 3-years is presented.

    Time frame: 3 years

07

Results

Posted Feb 2, 2024

Participant flow

Participant flow — Overall Study
MilestoneParticipants Less Than or Equal to 60 Years of AgeParticipants Greater Than 60 Years of Age
Started2915
Completed2814
Not completed11
Withdrew: Withdrawal by subject11

Outcome measures

PrimaryClinical Response to Crenolanib With Standard Induction Chemotherapy

To determine the response rate to crenolanib. Complete remission (CR) response criteria includes a post-baseline bone marrow (BM) biopsy or aspiration % blasts \<5%, the absence of Auer rods and extramedullary leukemia, absolute neutrophil count (ANC) \>1×10\^9/L and platelet count \>100×10\^9/L. Complete remission with incomplete blood count recovery (CRi) response includes all CR criteria met, except participant do not achieve either platelet or ANC recovery. Composite Complete CR response includes all subjects who achieve a CR and CRi. Partial Response (PR) response includes all CR criteria met except a decrease of ≥50% in % blasts in the BM aspirate or biopsy from baseline but within 5-25% or bone marrow blasts \<5% with persistent Auer rods. Refractory Disease response includes subjects who do not satisfy the criteria for CR, CRi or PR.

Time frame:
2 years
Reported as:
Count of participants · Participants
Clinical Response to Crenolanib With Standard Induction Chemotherapy
ParticipantsParticipants Less Than or Equal to 60 Years of AgeParticipants Greater Than 60 Years of AgeAll Patients
Composite Complete Remission (CR + CRi)261238
Complete Remission (CR)221234
Complete Remission with incomplete count recovery (CRi)404
Partial Remission (PR)011
Refractory Disease314
Not evaluable011
Secondary3-Year Overall Survival

Overall survival (OS) was measured from the date of the first dose of treatment to the date of death from any cause or to the last date that the patient was known to be alive. OS at 3-years is presented.

Time frame:
3 years
Reported as:
Number · percentage of participants
3-Year Overall Survival
percentage of participantsParticipants Less Than or Equal to 60 Years of AgeParticipants Greater Than 60 Years of AgeAll Patients
3-Year Overall Survival71.4 (56.5 to 90.3)33.3 (16.3 to 68.2)58 (44.9 to 74.9)

Adverse events

Collected over 3 years. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Participants Less Than or Equal to 60 Years of Age9/29 (31%)18/29 (62.1%)29/29 (100%)
Participants Greater Than 60 Years of Age10/15 (66.7%)12/15 (80%)15/15 (100%)
Most frequent serious events
Showing 10 of 54
Most frequent serious events
EventParticipants Less Than or Equal to 60 Years of AgeParticipants Greater Than 60 Years of Age
Febrile neutropeniaBlood and lymphatic system disorders7/294/15
SepsisInfections and infestations4/293/15
DehydrationMetabolism and nutrition disorders0/293/15
DiarrhoeaGastrointestinal disorders1/292/15
Gastrointestinal haemorrhageGastrointestinal disorders2/292/15
NauseaGastrointestinal disorders1/292/15
PyrexiaGeneral disorders2/292/15
PneumoniaInfections and infestations3/291/15
Respiratory failureRespiratory, thoracic and mediastinal disorders2/291/15
Abdominal painGastrointestinal disorders2/290/15
Most frequent other events
Showing 10 of 278
Most frequent other events
EventParticipants Less Than or Equal to 60 Years of AgeParticipants Greater Than 60 Years of Age
DiarrhoeaGastrointestinal disorders18/2912/15
Febrile neutropeniaBlood and lymphatic system disorders13/2911/15
NauseaGastrointestinal disorders16/2911/15
Oedema peripheralGeneral disorders10/299/15
Decreased appetiteMetabolism and nutrition disorders8/299/15
PyrexiaGeneral disorders8/298/15
VomitingGastrointestinal disorders15/297/15
Periorbital oedemaEye disorders3/297/15
FatigueGeneral disorders5/297/15
Aspartate aminotransferase increasedInvestigations6/297/15

Baseline characteristics

Age, Continuous
Age, Continuous(years)Participants Less Than or Equal to 60 Years of AgeParticipants Greater Than 60 Years of AgeTotal
Median51 (19 to 60)68 (61 to 75)57 (19 to 75)
Sex: Female, Male
Sex: Female, Male(Participants)Participants Less Than or Equal to 60 Years of AgeParticipants Greater Than 60 Years of AgeTotal
Female15722
Male14822
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Participants Less Than or Equal to 60 Years of AgeParticipants Greater Than 60 Years of AgeTotal
Hispanic or Latino101
Not Hispanic or Latino271542
Unknown or Not Reported101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Participants Less Than or Equal to 60 Years of AgeParticipants Greater Than 60 Years of AgeTotal
White221234
Asian325
Black or African American112
American Indian or Alaska Native101
Other202
FLT3 Mutations
FLT3 Mutations(Participants)Participants Less Than or Equal to 60 Years of AgeParticipants Greater Than 60 Years of AgeTotal
ITD only231033
TKD only448
ITD and TKD213
Cytogenetics
Cytogenetics(Participants)Participants Less Than or Equal to 60 Years of AgeParticipants Greater Than 60 Years of AgeTotal
Normal21930
Abnormal, not complex6511
Complex202
Not Available011
AML with Antecedent Hematological Disorders
AML with Antecedent Hematological Disorders(Participants)Participants Less Than or Equal to 60 Years of AgeParticipants Greater Than 60 Years of AgeTotal
No281240
Yes134
08

Study locations

9 sites
  • City of Hope Medical Center
    Duarte, California 91010, United States
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Weill Cornell Medical College
    New York, New York 10065, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Fred Hutchinson Cancer Research Center
    Seattle, Washington 98195, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2015, a primary completion of Dec 2019 and a completion of Dec 2019. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2024, 4 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2014
First posted
Nov 5, 2014
Start
Jan 2015
Primary completionActual
Dec 2019
CompletionActual
Dec 2019
Results first posted
Feb 2, 2024
Last update
Feb 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02283177
Lead sponsor
Arog Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Nov 5, 2014
Start date
Jan 2015
Primary completion
Dec 2019
Completion
Dec 2019
Results posted
Feb 2, 2024
Last update
Feb 2, 2024

Study contacts

Richard Stone, MD
principal investigator · Dana-Farber Cancer Institute
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion